Products

What will AGI do for Bicalutamide?

This classification denotes an anti-androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0Z3NAU9DP. European Medicines Agency schedules Bicalutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05817MIG. Bicalutamide generally arises in the molecular formula C18H14F4N2O4S. The term BICALUTAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) BICALUTAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bicalutamide under HS 29309085 and SITC 51549. As of Q4 2014, BICALUTAMIDE remains the US FDA Preferred Term for this commodity. Bicalutamide bears US NLM identifiers UMLS ID C0285590 and NCI Concept Code C1599. SMILES: S(=O)(=O)(CC(O)(C)C(=O)NC1CC(C(CC1)C#N)C(F)(F)F)C1CCC(F)CC1.

How AGI delivers it

Four ways AGI delivers for Bicalutamide

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bicalutamide, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bicalutamide, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bicalutamide connects

measured by

  • Active Ingredient Potencymodel
  • Assay Puritymodel
  • Compound Puritymodel
  • Impurity Contentmodel
  • Loss On Dryingmodel
  • Particle Size Distributionmodel
  • Residual Solventmodel